InflaRx presents kidney data while InflaRx stock costs EUR 1.37

Published on 10/22/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

InflaRx presents izicopan data at Kidney Week on October 22, 2026. InflaRx stock costs EUR 1.37 at Lang & Schwarz.

Clinical program and market context

Izicopan data were presented on October 22, 2026, after at least 90.00 percent C5a blockade over 14 days.
Gabriela Alperovich joined InflaRx on October 1, 2026, with more than 20 years of pharmaceutical experience.
InflaRx stock trades at EUR 1.37 at 1:46 p.m. CEST at Lang & Schwarz on October 22, 2026.
Needham initiated coverage with a USD 8.00 target on September 14, 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx N.V. (ISIN NL0012661870) presented new izicopan kidney-disease data at the American Society of Nephrology's Kidney Week on October 22, 2026. The late-breaking poster follows a company announcement that described at least 90.00 percent blockade of C5a-induced neutrophil activation over 14 days, according to GlobeNewswire on October 2, 2026.

Izicopan carries the clinical story

The poster concerns izicopan, an oral small-molecule inhibitor of the C5a receptor that InflaRx is developing for ANCA-associated vasculitis and additional renal diseases. The release said first-in-human studies found no safety signals of concern across single doses from 3 mg to 240 mg and multiple doses from 30 mg once daily to 90 mg twice daily.

InflaRx's development focus has also gained a new clinical leader. Gabriela Alperovich became senior vice president and global head of clinical development on October 1, 2026, bringing more than 20 years of pharmaceutical-industry experience, according to Investing.com.

What does the target imply?

Needham initiated coverage with a Buy rating and a USD 8.00 price target on September 14, 2026, while MarketBeat listed nine brokerage ratings and an average 12-month target of USD 7.43 on October 13, 2026. The targets sit beside a development program that still depends on clinical execution and future regulatory progress, rather than commercial revenue.

Three dates frame the program

On September 21, 2026, InflaRx announced a virtual Capital Markets Day scheduled for November 3, 2026, at 8:00 a.m. EST. On October 1, 2026, it appointed Alperovich after more than 20 years in the pharmaceutical industry. On October 2, 2026, it announced the October 22 Kidney Week poster and the at least 90.00 percent blockade result.

Upcoming company dates

The Kidney Week poster was scheduled for October 22, 2026, while the Capital Markets Day is scheduled for November 3, 2026, according to the company investor-relations page.

Stock stays tied to clinical milestones

InflaRx was last at USD 1.55 on Nasdaq on October 21, 2026, at 4:00 p.m. ET. Its market capitalization was USD 228.4 million, with a 52-week range of USD 0.80 to USD 2.95 on that date. At Lang & Schwarz, the stock was trading at EUR 1.37 on October 22, 2026, at 1:46 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of IFRX stock.